Categories
Resource Centre - Media & Press

You’re Part of Something Bigger”: Delivering Lifesaving COVID-19 Diagnostic Tests in South Africa

Getting tests into hands: delivering rapid diagnostic tests to South Africa

In June 2021, a large shipment of COVID-19 diagnostic tests procured by the Global Fund through their Pooled Procurement Mechanism arrived in South Africa.

Part of the order was 648 000 rapid antigen tests that produced results within 15 minutes for community health workers and medical personnel working on the front lines.

At the time, the country saw a rapid rise in infections caused by the Delta variant. The rollout of vaccines to the general public only started in July that year, with the elderly getting priority access.

All hands on deck
Logistics personnel interviewed by the Global Fund reported early-morning queues on average 100 metres long at testing sites, as people tried to access possible diagnoses in response to the new infection wave.

The test kits delivered in South Africa were manufactured in South Korea, flown via Ethiopia to a warehouse in Johannesburg, and sorted and distributed throughout the country. 

The supply chain also faced several problems, including a shortage of shipping containers, resulting in delays in deliveries of essential products, such as personal protective equipment. Logistics personnel also feared theft and hijacking.

By 1 July 2021, the Global Fund has procured 21.5 million diagnostic tests worldwide.

Categories
Resource Centre - Media & Press

Global Fund, United States and Unitaid Launch “Test-and-Treat” Programs at Second Global COVID-⁠19 Summit

Global Health Summit 2021: Rome Declaration signals world leaders’ commitment to fighting future pandemics.

On May 21, 2021, leaders of the G20 countries and other states signed the Rome Declaration signaling their commitment to fighting the current Covid-19 pandemic and agreeing to a set of principles to prepare and fight future pandemics.

What is the Rome Declaration?

The Rome Declaration signals a commitment from world leaders to overcome the Covid-19 pandemic and prevent and prepare for future pandemics. It was signed in May 2021 in Rome.

What does it say?

The Rome Declaration reaffirms the Covid-19 pandemic to be an unprecedented global health and socio-economic crisis that has disproportionately affected the most vulnerable communities, including women, girls, children, frontline workers, and the elderly.

It signals an agreement that all countries must work together to bring the disease under control, including working together for the equitable distribution of vaccines, therapeutics, diagnostics, personal protective equipment and treatment, supply chains, and boost and diversify global vaccine-manufacturing capacity.

What principles did leaders agree to support?

It also is a commitment that underlines sustained investments in global health towards achieving Universal Health Coverage with primary healthcare at its center will be essential for the future.

 It recognizes the setbacks to achieving the Sustainable Development Goals caused by the pandemic.

The declaration also supported addressing the ACT-A funding gap to help it fulfill its mandate. The ACT-Accelerator has a funding gap of US$ 329 million for work planned up to 31 March 2023.

Significantly the declaration also noted proposals on a possible international instrument or agreement concerning pandemic prevention and preparedness.

The signatories also agreed on principles for future conduct in preparing, preventing, detecting, and responding to global pandemics.

These principles include support for the WHO as the center of a global pandemic response, sustainability, inclusivity,  resilient recovery, and support for the One Health approach addressing risks emerging from the human-animal-environment interface, the threat of anti-microbial resistance.

Categories
Resource Centre - Media & Press

Global Fund, United States and Unitaid Launch “Test-and-Treat” Programs at Second Global COVID-⁠19 Summit

Why do we not use antibody tests to diagnose COVID-19 infections?

Checking for antibodies is not the most accurate indicator of the presence of a SARS-COV-2 infection.

What are antibody tests?

This article explains the role antibody tests are playing in fighting the pandemic. 

Antibodies neutralize foreign cells the body sees as a threat. Most COVID-19 vaccines trigger the body to produce antibodies against the spike protein in the SARS-COV-2 virus. 

The spike protein is a molecule found on the surface of the virus, and it helps the virus to enter the host cells and spread from there. 

Why can’t we use antibody testing to measure vaccine efficacy?

COVID-19 serology tests were designed early in the pandemic to detect only a few antibodies generated by natural infection, not vaccine-induced immunity.

They detect antibodies produced to fight the protein capsule around the virus and not the spike protein, while most COVID-19 vaccines introduce the body to small amounts of the genetic material in the spike protein to elicit an immune reaction.

Can antibody testing determine if a vaccine worked?

Not precisely. It takes around two weeks for the body to generate antibodies after COVID-19 vaccination, so even tests to detect the “right” antibody could be negative in the first few weeks after vaccination. 

Can antibody tests be wrong?

The United States Food and Drug Administration (FDA) has recommended that antibody testing not be used to evaluate either immunity levels or protection levels from SARS-COV-2.

Why still do antibody tests?

Data from antibody tests are helpful for surveillance studies. In these studies, large numbers of people in a community are tested. These studies estimate how many people were infected in the past and how fast the virus spreads. 

Categories
Resource Centre - Media & Press

Redesigning systems to focus on people, not pathogens: A conversation with Dr Fifa Rahman and Dr Bill Rodriguez

Focus on the humans, not the virus: Better diagnostics are crucial for more robust, pandemic-proof primary healthcare

In this podcast, Dr. Bill Rodriguez and Dr. Fifa Rahman discuss why it is vital to improve access to Covid-19 diagnostics and strengthen primary healthcare systems to make humans, rather than the SARS-COV-2 virus, the focus of the global pandemic response. 

Creating human-centered health systems

“It has been about the virus and not about the people for a very long time,” Rodriguez said.

Rodriquez and Rahman both highlight that globally there must be a shift in focus from the SARS-COV-2 virus to the humans affected by it. 

They agree that the focus must be on strengthening primary healthcare systems and designing diagnostics and digital tools to enable the treatment of people with respiratory symptoms at a community level. 

Fighting paternalism

Rahman emphasized that this would mean fighting paternalism at a global level. She used the example that global health decision-makers raised concerns if people in lower-income countries could read the results of self-tests for Covid-19 and act on it, even though self-tests for HIV and pregnancy have been around for a long time.

Communities must become the focus

Rodriques said decision-makers, primarily male and European, needed more input on what was happening at a community level.

He said a clear example of this was that it took global health organizations two years to finalize a policy recommendation on self-testing. One of the concerns raised was that it would not be possible to collect data on the virus if people self-test. 

At the same time, Rahman pointed out; there was a genuine risk of Covid-19 spreading in a community while people had to wait for days to access test results done at a laboratory.

“We would be negligent if we do not take this opportunity to redesign the system,” Rodriquez said.

He stressed that strengthening public healthcare systems should be a priority in preparing for the next pandemic.

Dr. Bill Rodriguez is the CEO of FIND, the global alliance for diagnostics. Dr. Fifa Rahman is the Principal Consultant at Matahari Global Solutions and a Permanent NGO Representative at the WHO Access to COVID-19 Tools Accelerator.

Categories
Resource Centre - Media & Press

Vaccines Alone Won’t Defeat the Variants

Why do we not use antibody tests to diagnose COVID-19 infections?

Checking for antibodies is not the most accurate indicator of the presence of a SARS-COV-2 infection.

What are antibody tests?

This article explains the role antibody tests are playing in fighting the pandemic. 

Antibodies neutralize foreign cells the body sees as a threat. Most COVID-19 vaccines trigger the body to produce antibodies against the spike protein in the SARS-COV-2 virus. 

The spike protein is a molecule found on the surface of the virus, and it helps the virus to enter the host cells and spread from there. 

Why can’t we use antibody testing to measure vaccine efficacy?

COVID-19 serology tests were designed early in the pandemic to detect only a few antibodies generated by natural infection, not vaccine-induced immunity.

They detect antibodies produced to fight the protein capsule around the virus and not the spike protein, while most COVID-19 vaccines introduce the body to small amounts of the genetic material in the spike protein to elicit an immune reaction.

Can antibody testing determine if a vaccine worked?

Not precisely. It takes around two weeks for the body to generate antibodies after COVID-19 vaccination, so even tests to detect the “right” antibody could be negative in the first few weeks after vaccination. 

Can antibody tests be wrong?

The United States Food and Drug Administration (FDA) has recommended that antibody testing not be used to evaluate either immunity levels or protection levels from SARS-COV-2.

Why still do antibody tests?

Data from antibody tests are helpful for surveillance studies. In these studies, large numbers of people in a community are tested. These studies estimate how many people were infected in the past and how fast the virus spreads. 

Categories
Resource Centre - Media & Press

COVID-19: why we can’t use antibody tests to show that vaccines are working

Why do we not use antibody tests to diagnose COVID-19 infections?

Checking for antibodies is not the most accurate indicator of the presence of a SARS-COV-2 infection.

What are antibody tests?

This article explains the role antibody tests are playing in fighting the pandemic. 

Antibodies neutralize foreign cells the body sees as a threat. Most COVID-19 vaccines trigger the body to produce antibodies against the spike protein in the SARS-COV-2 virus. 

The spike protein is a molecule found on the surface of the virus, and it helps the virus to enter the host cells and spread from there. 

Why can’t we use antibody testing to measure vaccine efficacy?

COVID-19 serology tests were designed early in the pandemic to detect only a few antibodies generated by natural infection, not vaccine-induced immunity.

They detect antibodies produced to fight the protein capsule around the virus and not the spike protein, while most COVID-19 vaccines introduce the body to small amounts of the genetic material in the spike protein to elicit an immune reaction.

Can antibody testing determine if a vaccine worked?

Not precisely. It takes around two weeks for the body to generate antibodies after COVID-19 vaccination, so even tests to detect the “right” antibody could be negative in the first few weeks after vaccination. 

Can antibody tests be wrong?

The United States Food and Drug Administration (FDA) has recommended that antibody testing not be used to evaluate either immunity levels or protection levels from SARS-COV-2.

Why still do antibody tests?

Data from antibody tests are helpful for surveillance studies. In these studies, large numbers of people in a community are tested. These studies estimate how many people were infected in the past and how fast the virus spreads. 

Categories
Add Resources - Awareness & Advocacy Resource Centre - Media & Press

Low testing rates and constrained access to vaccines – a deadly combination?

Diagnostics constitutes the most significant funding gap within the ACT Accelerator”

Low testing rates and constrained access to vaccines – a deadly combination?


In this opinion piece Peter Sands, Director of the Global Fund to Fight AIDS, tuberculosis, and malaria, and Emma Hannay, Find’s Chief Access Officer, argue for a global refocus on testing to fight the COVID-19 pandemic.

They highlight the stark inequalities in COVID-19 testing between high-, middle- and low-income countries, saying that this can create conditions for a more severe and contagious mutation of SARS-COV-2 to emerge unnoticed.

The authors add that diagnostics constitutes the most significant funding gap within the ACT Accelerator.


The statistics:

  • Germany offers a free test a week
  • England offers two free tests a week
  • Lower-income countries can only test 7 people for every 100 000
  • For every test done in lower-income countries, high-income countries test 86 people
  • According to a survey of 24 African countries, only 11% could offer rapid COVID-19 tests, and only 8% could provide PCR tests
  • Globally, there is an $8.7-billion shortfall in testing and lab capacity. Box ends

“The low availability of testing, coupled with constrained access to vaccines, create a perfect environment for new, more contagious, and perhaps more deadly strains of the COVID-19 virus to emerge without initial notice, putting even vaccinated populations at risk” – Peter Sands and Emma Hannay.

Categories
Add Resources - Awareness & Advocacy Resource Centre - Media & Press

One year into the Covid-19 pandemic, testing is as vital as ever

Why do we not use antibody tests to diagnose COVID-19 infections?

Checking for antibodies is not the most accurate indicator of the presence of a SARS-COV-2 infection.

What are antibody tests?

This article explains the role antibody tests are playing in fighting the pandemic. 

Antibodies neutralize foreign cells the body sees as a threat. Most COVID-19 vaccines trigger the body to produce antibodies against the spike protein in the SARS-COV-2 virus. 

The spike protein is a molecule found on the surface of the virus, and it helps the virus to enter the host cells and spread from there. 

Why can’t we use antibody testing to measure vaccine efficacy?

COVID-19 serology tests were designed early in the pandemic to detect only a few antibodies generated by natural infection, not vaccine-induced immunity.

They detect antibodies produced to fight the protein capsule around the virus and not the spike protein, while most COVID-19 vaccines introduce the body to small amounts of the genetic material in the spike protein to elicit an immune reaction.

Can antibody testing determine if a vaccine worked?

Not precisely. It takes around two weeks for the body to generate antibodies after COVID-19 vaccination, so even tests to detect the “right” antibody could be negative in the first few weeks after vaccination. 

Can antibody tests be wrong?

The United States Food and Drug Administration (FDA) has recommended that antibody testing not be used to evaluate either immunity levels or protection levels from SARS-COV-2.

Why still do antibody tests?

Data from antibody tests are helpful for surveillance studies. In these studies, large numbers of people in a community are tested. These studies estimate how many people were infected in the past and how fast the virus spreads. 

Categories
Featured Work - Scaling Up & Sustainability

The Global Fund’s COVID-19 Response Mechanism (C19RM)

First established in April 2020, the Global Fund’s COVID-19 Response Mechanism (C19RM) was designed to rapidly respond to the global health emergency created by SARS-CoV-2. Building on 20 years of experience in fighting three of the deadliest infectious diseases, and using its comparative advantages in procurement, deployment at scale and existing relationships with implementing countries and communities, the Global Fund was swiftly able to step up its COVID-19 response.

Since first establishing C19RM, the Global Fund has been able to expand, refine and develop the mechanism. It learned lessons and responded as the pandemic evolved and adapted to changing country needs and the availability of new tools such as self-testing and oral antivirals.

Through C19RM, the Global Fund has been the primary source of funding for all COVID-19 tools, except vaccines. Thanks to the generous backing of donors, the Global Fund has awarded over US$4.9 billion since March 2020 to 109 low- and middle-income countries (LMICs) and 22 multi-country programs, to support health and community health workers and communities fight and recover from COVID-19.  

The Global Fund has been able to support LMICs in responding to the new virus, mitigating the knock-on impact on HIV, TB and malaria programs and protecting the health services. C19RM support included providing access to diagnostics, oxygen, therapeutics, and personal protective equipment (PPE) at a time of unprecedented global demand, as well as adapting lifesaving HIV, TB and malaria services and investing to reinforce overstretched health systems, including supporting community health workers.

In addition to provision of COVID-19 tools, countries were encouraged to invest in crucial Community interventions, such as responding to human rights and gender related barriers to services, community-led monitoring, community-led advocacy and research, social mobilization, building community linkages and coordination, institutional capacity building, planning and leadership development, and gender-based violence (GBV) prevention. Working through the community engagement strategic initiative partners, communities and civil society were able to access technical support to engage in the process.  

C19RM on Diagnostics

From the start of the pandemic, the Global Fund took a leading role in supporting LMICs to scale up testing for the new virus, based on 20 years of experience in procuring diagnostics and investing in laboratory capacities.

C19RM investments have backed countries’ efforts to address the acute difficulties in sourcing PCR and rapid antigen diagnostic tests (Ag-RDT) and scaling-up testing in response to COVID-19 – including supply-side constraints, high costs, quality issues, long delivery times and delays in the issuance of guidance on testing strategies. C19RM procured PCR tests and Ag-RDTs, strengthened laboratory systems and network capacities, and reinforced national testing strategies and governance. In the first phase of the pandemic, the Global Fund worked closely with ACT-Accelerator partners to ensure equitable allocation of the extremely limited volume of PCR diagnostics then available to LMICs, while working to secure greater production capacity, negotiate pricing and tackle implementation bottlenecks. Following the introduction of WHO-approved Ag-RDTs in September 2020, the Global Fund encouraged their deployment and the introduction of community-based testing and self-testing.

Alongside large-scale procurement and deployment of diagnostics, the Global Fund has also been supporting technical capacity building through Project STELLAR, supporting a group of 23 African countries in scaling-up COVID-19 testing, including wastewater testing, improving diagnostic governance and data management, and galvanizing longer term strengthening of laboratory systems, a key component of resilient and sustainable health systems.

In 2023, as the acute phase of the disease had passed and COVID-19 is becoming endemic in many countries, the priorities of implementing countries have shifted towards longer-term investments in health infrastructure and capacities for pandemic preparedness. To respond to counties’ needs, C19RM priorities have shifted to strengthening key components of an effective health system, especially laboratory systems, surveillance, human resources (including community health workers), supply chain management, oxygen and respiratory care, infection prevention and control (IPC), pandemic preparedness and response (PPR) and sustainable waste management. In addition, the Global Fund continues to work towards limiting the impact of COVID-19 on high-risk populations in LMICs through Test and Treat integrated service delivery models. Key activities include facilitating access to novel treatments and providing technical assistance to integrate treatment into existing public health infrastructure.

To learn more, visit the Global Fund’s C19RM page

Categories
Add Resources - Scaling Up & Sustainability

Nigerian study on public acceptance of COVID-19 self-testing

This article, published in BMJ Open in January 2023, details a study on people’s willingness to use COVID-19 self-testing in Nigeria.

Nigeria has been badly affected by the COVID-19 pandemic, and poor testing coverage in the country may make controlling the spread more difficult.

This original research is a cross-sectional survey to assess the general public’s acceptability of SARS-CoV-2 self-testing as an approach to help address this challenge.

It concluded that most Nigerians agree with the concept of self-testing and would act to protect public health if they self-tested positive.

Read more here